Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: A Southwest Oncology Group study

Holly H. Gallion, P. Y. Liu, David E. Alberts, Robert V. O'Toole, Janet O'Sullivan, Glenn Mills, Harriet O. Smith, Harry E. Hynes

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Twenty-three patients with metastatic or recurrent Stage III or IV epithelial ovarian cancer who were refractory to or relapsed following previous chemotherapy with cisplatin or a cisplatin analog were entered into a phase II study of amonafide. The starting dose of amonafide was 300 mg/m2 delivered daily over 1 hr by intravenous infusion. In the absence of myelosuppression, the dose of amonafide was escalated by increments of 75 mg/m2 to a maximum of 450 mg/m2. There were 19 eligible and 17 fully evaluable patients. Grade 3 or 4 leukopenia occurred in 14 (74%) patients and grade 3 or 4 thrombocytopenia in 6 (32%) patients. No objective complete or partial responses were observed. Four patients had stable disease for 3, 4, 4.5, and 6 months, respectively. Therefore, amonafide in the doses used in the present trial does not have significant activity in previously treated patients with ovarian cancer.

Original languageEnglish (US)
Pages (from-to)230-232
Number of pages3
JournalGynecologic Oncology
Volume46
Issue number2
DOIs
Publication statusPublished - Aug 1992

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Gallion, H. H., Liu, P. Y., Alberts, D. E., O'Toole, R. V., O'Sullivan, J., Mills, G., ... Hynes, H. E. (1992). Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: A Southwest Oncology Group study. Gynecologic Oncology, 46(2), 230-232. https://doi.org/10.1016/0090-8258(92)90261-G